The Bio Report

As concerns about the use of animals to test drugs, scientist have sought new ways to analyze the efficacy and toxicity of their products. Genoskin is seeking to enable better, faster, and safer drug development through the use of its proprietary ex vivo human skin platforms for preclinical drug testing. The company provides natural human skin obtained from patients that it maintains in a living and functional state. We spoke to Pascal Descargues, founder and CEO of Genoskin, about the company’s ex vivo human skin models, how they provide an alternative to animal experiments, and how they can accelerate the generation of reliable human data in drug development.